About Us

Archives






Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

Posted: June 22, 2021 at 1:49 am


SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principia’s portfolio including BTK targeted agents. During her tenure at Principia, she successfully guided drug pipeline strategy and led many functions over time, including the company’s manufacturing and technical operations, regulatory and quality, clinical operations, project and portfolio management, medical affairs, commercial and communications functions until its acquisition by Sanofi in September, 2020.

Follow this link:
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.